New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 8, 2013
10:52 EDTCLDXCelldex stages turnaround, levels to watch
The stock is a mirror image of yesterday's sharp downside action following earnings, that later saw the shares level out to close near the opening gap price near $10.50. Today the stock is up over 13.5%, last at $11.91. Several firms, Cantor, Roth Capital, and Jefferies all raised price targets on the shares this morning, ranging from $15 to $16. At current levels, next resistance is at $12.53, a prior pivot high. Support is at $11.36.
News For CLDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
18:51 EDTCLDXCelldex 7.25M share Secondary priced at $24.00
Subscribe for More Information
February 24, 2015
16:00 EDTCLDXCelldex files to sell 7.25M shares of common stock
Subscribe for More Information
07:15 EDTCLDXCelldex reports Q4 EPS (36c), consensus (35c)
Subscribe for More Information
February 23, 2015
09:25 EDTCLDXOn The Fly: Pre-market Movers
Subscribe for More Information
08:08 EDTCLDXCelldex rindopepimut receives FDA breakthrough therapy designation
Celldex Therapeutics announced that the FDA has granted rindopepimut Breakthrough Therapy Designation for the treatment of adult patients with EGFRvIII-positive glioblastoma, or GBM. This application was based on data from the Phase 2 ReACT study in recurrent GBM, the Phase 2 ACT III study in newly diagnosed GBM and additional supportive Phase 2 studies. An international Phase 3 study of rindopepimut, called ACT IV, in newly diagnosed GBM completed enrollment in December of 2014.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use